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Local delivery of doxorubicin through
supramolecular peptide amphiphile nanofiber
gels†
Goksu Cinar, Ayse Ozdemir, Seren Hamsici, Gokhan Gunay, Aykutlu Dana,
Ayse B. Tekinay* and Mustafa O. Guler*
Peptide amphiphiles (PAs) self-assemble into supramolecular nanofiber gels that provide a suitable
environment for encapsulation of both hydrophobic and hydrophilic molecules. The PA gels have signifi-
cant advantages for controlled delivery applications due to their high capacity to retain water, biocompat-
ibility, and biodegradability. In this study, we demonstrate injectable supramolecular PA nanofiber gels for
drug delivery applications. Doxorubicin (Dox), as a widely used chemotherapeutic drug for breast cancer
treatment, was encapsulated within the PA gels prepared at different concentrations. Physical and chemi-
cal properties of the gels were characterized, and slow release of the Dox molecules through the supra-
molecular PA nanofiber gels was studied. In addition, the diffusion constants of the drug molecules within
the PA nanofiber gels were estimated using fluorescence recovery after the photobleaching (FRAP)
method. The PA nanofiber gels did not show any cytotoxicity and the encapsulation strategy enhanced
the activity of drug molecules on cellular viability through prolonged release compared to direct adminis-
tration under in vitro conditions. Moreover, the local in vivo injection of the Dox encapsulated PA
nanofiber gels (Dox/PA) to the tumor site demonstrated the lowest tumor growth rate compared to the
direct Dox injection and increased the apoptotic cells within the tumor tissue for local drug release
through the PA nanofiber gels under in vivo conditions.
Introduction
Drug delivery systems have been developed to control drug
release rates, maintain the drug concentration within thera-
peutic levels, improve the drug bioavailability and reduce
potential side effects by lowering the therapeutic dosages
necessary for treatment.1 A variety of organic/inorganic
materials, devices or formulations have been used as delivery
vehicles to develop effective therapeutic modalities.1,2
Advances in materials science and nanotechnology have pro-
vided a new generation of biodegradable and biocompatible
delivery systems with considerable control over size, shape and
functionality.2–5
Self-assembly is a nature-inspired engineering tool that
allows the construction of drug delivery systems with distinct
chemical and physical properties.6 Polymers, synthetic or
natural biomacromolecules, peptides, lipids or hybrid systems
can be produced from relatively simple “building blocks”
through multiple non-covalent interactions, hydrogen bonding
and hydrophobic, aromatic, hydrophilic and electrostatic inter-
actions. Although these interactions are individually weak and
easily reversible compared to the covalent systems,7 the com-
bined effect of multiple non-covalent forces is able to drive the
self-assembly process and result in the formation of complex,
adaptable and highly tunable structures as drug delivery
architectures.8
Among self-assembled materials, peptide amphiphiles
(PAs) consisting of an aliphatic alkyl tail and hydrophilic
amino acids can form diverse nanostructures and supramole-
cular architectures in response to different factors such as the
pH change,9 presence of oppositely charged molecules10,11 or
electrolyte addition12 and enzyme activation.13 The PA assem-
blies provide structural organization for delivery of both hydro-
phobic and hydrophilic therapeutic moieties, which can be
modulated through the design of building blocks.7,14–16
Moreover, targeted high efficacy delivery of small therapeutics
can be achieved through functionalization of PA nano-
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structures with ligand-binding, cell-penetrating and internaliz-
ation-associated peptide sequences.17,18 Biocompatibility and
biodegradability of the PA assemblies through different
proteases19–21 also enhance their utility as delivery architec-
tures, especially for chemotherapeutics that show high cyto-
toxicity when administered directly to the blood stream.
Previously, it was shown that bioresponsive anticancer drug
delivery was sustained through self-assembled PA nanofiber
gels containing matrix metalloproteinase-2 (MMP-2) cleavable
amino acid sequences.22 In another study, noncovalent encap-
sulation of a hydrophobic anti-tumor drug into self-assembled
PA nanofibers was shown both to enhance the aqueous solubi-
lity of the drug and to increase its efficiency against an in vivo
breast cancer model.23
Local delivery of anticancer drugs using biocompatible
scaffolds can be an alternative way to reduce systemic side
effects on healthy tissues by improving their bioavailability at
the target site.24–27 Self-assembled peptide nanofiber gels have
been investigated extensively for controlled delivery of small
molecules including proteins,28 antibodies29 and
therapeutics,30–33 and are attractive candidates for local delivery
of chemotherapeutics.22 The design of injectable peptide based
gel systems has been presented in several studies.34–36 Recently,
a β-hairpin peptide hydrogel developed as an injectable local
drug delivery system was found to facilitate the continuous
release of active chemotherapeutics for over a month.37
Doxorubicin (Dox) is an FDA approved and clinically used
chemotherapeutic molecule for the treatment of various
cancer types.38,39 Despite its widespread use, the intravenous
injection of Dox may cause severe health problems in
patients.40,41 In this study, we aimed to develop biocompatible,
biodegradable and injectable PA nanofiber gels which provide
both hydrophilic and hydrophobic nanofibrous environments
for local delivery of drug molecules overcoming the limitations
of Dox treatment. For this purpose, oppositely charged PA
molecules were designed as the building blocks of self-
supporting gels that are able to encapsulate drug molecules
with 100% efficiency during sol–gel transition at pH 7.4 in
water. The chemical and physical properties of nanofibrous PA
networks including their secondary structure, concentration-
dependent viscoelastic behaviors and injectability were studied
using several characterization techniques. The biodegradabil-
ity of the coassembled PA gels by different proteases was also
tested under physiological conditions. Furthermore, the con-
trolled release of Dox was investigated through in vitro bulk
release experiments and fluorescence recovery after the photo-
bleaching (FRAP) technique. Transport parameters, including
diffusion coefficients and immobile fractions of drug mole-
cules within the PA nanofiber gels, were estimated using a
semi-empirical method. In addition, in vitro biocompatibility
of the PA nanofiber gels and the effect of controlled drug
release on cellular viability were studied to assess the anti-
tumor efficiency of Dox encapsulated PA nanofiber gels.
Finally, the potential of the PA nanofiber gel as a local drug
delivery system was examined in a mouse model of breast
cancer under in vivo conditions.
Experimental section
Materials
All protected amino acids, rink amide 4-methyl-
benzhydrylamine (MBHA) resin, Fmoc-Glu(OtBu)-Wang resin
(100–200 mesh) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HBTU) were purchased
from NovaBiochem. Other chemicals including dichloro-
methane (DCM), dimethylformamide (DMF), acetonitrile,
piperidine, acetic anhydride, N,N-diisopropylethylamine
(DIAE), trifluoroacetic acid (TFA), uranyl acetate and doxo-
rubicin hydrochloride were purchased from Fisher, Merck, Alfa
Aesar or Sigma-Aldrich. Proteolytic enzymes (proteinase K
from Tritirachium album and α-chymotrypsin) from bovine pan-
creas were purchased from VWR and Sigma, respectively. All
chemicals and solvents used in this study were analytical
grade.
Peptide amphiphile synthesis and characterization
E3PA (Lauryl-VVAGEEE) and K3PA (Lauryl-VVAGKKK-Am) were
synthesized according to a previously described solid phase
9-fluorenylmethoxycarbonyl (Fmoc) peptide synthesis
method.11 Rink amide MBHA resin served as the solid support
for K3PA synthesis while Fmoc-Glu(OtBu)-Wang resin was used
as a solid support for E3PA synthesis. An Agilent 1200 series
reverse-phase high performance liquid chromatograph (HPLC)
equipped with an Agilent 6224 high resolution mass time-of-
flight (TOF) mass spectrometer and an electrospray ionization
(ESI) source was used for the characterization of the syn-
thesized PAs (Fig. S1†). 1 mg mL−1 E3PA in water was analyzed
at pH 7 using an Agilent Zorbax 300SB-C18, 3.5 µm (100 ×
4.6 mm) column in a gradient of water (0.1% NH4OH) and
acetonitrile (0.1% NH4OH) as the mobile phase, while an
Agilent Zorbax Extend-C18, 3.5 µm 80A (100 × 4.6 mm) column
was used for the analysis of 1 mg mL−1 K3PA at pH 7 in water
in an optimized gradient of water (0.1% formic acid) and
acetonitrile (0.1% formic acid). The mobile phase was opti-
mized as 2% acetonitrile at the first 2 min, then gradually
increased to 98% acetonitrile between 2 and 16 min, and
finally returned to 2% acetonitrile for the last 2 min.
Preparation of supramolecular PA nanofiber gels
E3PA and K3PA were separately dissolved in water, and the pH
of the individual solutions was adjusted to 7.4 using 1 M
NaOH. The negatively charged E3PA solution was mixed with
the positively charged K3PA solution in a 3 : 4 volumetric ratio
to trigger the coassembly of PAs into supramolecular nano-
fiber gels through overall charge neutralization. The final PA
concentrations within the coassembled gels were 3, 2, 1 and
0.5% (w/v), respectively.
Imaging of PA nanofibers and supramolecular gels
For the TEM imaging of individual PA nanofibers, 1% (w/v) PA
gel was diluted by the addition of water, and the sample was
cast onto a TEM grid. The sample was then stained with 2%
(w/v) uranyl acetate, air-dried, and imaged using a FEI Tecnai
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G2 F30 TEM instrument. For SEM imaging, the coassembled
PA nanofiber gels at 3, 2, 1 and 0.5% (w/v) concentrations were
prepared at pH 7.4 and in water. The water content in the gels
was replaced by a series of ethanol (40%, 60%, 80% and 100%)
concentrations to preserve their nanofibrous architecture
during critical point drying (CPD). The samples were coated
with 6 nm Au/Pd and imaged using a FEI Quanta 200 FEG
Scanning Electron Microscope.
Zeta potential measurements
E3PA and K3PA solutions were prepared at 0.186 mM and
0.132 mM concentrations, respectively and the pH of the solu-
tions was adjusted to 7.4 using 1 M NaOH. PA mixtures were
prepared by continuously adding E3PA in 0.4 ml increments
onto 10 ml of K3PA solution. After each addition of E3PA, the
mixture was mixed and the zeta potential of the mixture was
measured using a Malvern Nano-ZS ZetaSizer equipped with a
titrator and pH meter.
Secondary structure analysis using CD and FT-IR
For CD analysis, the coassembled PA gel was prepared accord-
ing to the above protocol. The gel was then diluted to
0.272 mM prior to analysis. Individual solutions of E3PA and
K3PA solutions were also prepared at the same concentrations
as the control. A Jasco J-815 CD spectrophotometer was used
for spectral analysis between 190 and 300 nm. For FTIR
measurement, 1% (w/v) PA gel was formed on Petri dishes and
instantly frozen in liquid nitrogen in order to preserve its
architectural integrity. The frozen sample was kept at −80 °C
overnight and then freeze-dried to remove its water content.
1 mg dried gel powder was mixed with 100 mg KBr to prepare
KBr pellets for analysis. A Bruker VERTEX 70 FTIR spectro-
meter was used for the measurements between 300 and
4000 cm−1.
Oscillatory rheology
Time sweep analysis of the coassembled PA nanofiber gels at
3, 2, 1 and 0.5% (w/v) concentrations was performed for 1 h at
pH 7.4 at a constant angular frequency and a strain of 10 rad s−1
and 0.1%, respectively. The sample volume was determined
as 250 µL with a 0.5 mm measuring distance from the stage.
An Anton Paar MCR-301 Rheometer with a 25 mm PP25-
SN17979 measuring device was used for the measurements.
1% (w/v) PA gel was also mixed within a syringe and injected
through a 1/2 inch 26 gauge needle to the rheometer stage to
determine the potential effect of injection on gel properties.
The same parameters given above were also used for the ana-
lysis of the syringe-injected gel.
Biodegradability of supramolecular PA nanofiber gels by
different proteases
308 µL of 1% (w/v) PA gels were prepared in glass vials accord-
ing to the gel preparation protocol explained above. Tare
weights of the vials were also noted prior to sample prepa-
ration. The gels were then treated with 1 ml proteinase K
or α-chymotrypsin solutions, prepared at a concentration of
1 mg ml−1 in 50 mM Tris buffer at pH 8. As a control group,
Tris buffer without enzymes was also placed on the PA gels
and the samples were weighed at the determined time inter-
vals by removing the buffer solutions. After each measure-
ment, freshly prepared buffer with or without the enzymes was
replaced onto the gels. The experiment was conducted for
25 days, at which point the PA gels treated with proteinase K
were found to have completely disappeared.
Drug encapsulation and controlled release experiments
For drug encapsulation, E3PA and K3PA solutions at 3, 2, 1 and
0.5% (w/v) concentrations were prepared at pH 7.4 in water. A
stock solution of Dox (833.3 µM) was also prepared in water.
The stock drug solution initially was mixed with positively
charged K3PA and then co-assembly was triggered by addition
of the negatively charged E3PA at pH 7.4 in water at a 3 : 4 volu-
metric ratio. A final Dox concentration of 40 μM was encapsu-
lated within 100 μL of PA gels prepared in small vials. After 2 h
of incubation, 100 μL of water was added onto the PA gels, and
Dox release was monitored at pre-determined time intervals by
removing 1 μL of the sample for fluorescence-based concen-
tration determination using a ThermoScientific Nanodrop
3300 spectrophotometer. After each measurement, the same
amount of the water was added back to the gel samples. The
measurements were replicated for 4 different groups for each
gel concentration. λexcitation and λemission values of 565 and
630 nm were used for the measurements; and the maximum
RFU value at 588 nm was recorded for fluorescence analysis.
FRAP measurements
SNOM confocal Raman microscopy was used for FRAP experi-
ments at 200× magnification. The area was initially monitored
by pre-bleach scanned images at low laser intensity, bleached
at 100% laser intensity (40 mW) for 15 s, and subsequently fol-
lowed by detection of the fluorescence recovery again at low
intensity. Dox encapsulated PA gels at 3, 2, 1 and 0.5% (w/v)
concentrations were prepared according to the protocol given
above. Instead of small vials, the Dox encapsulated gels were
prepared within closed Petri dishes to prevent drying. The
final Dox concentration within the PA gels was 40 µM.
In vitro studies
The 4T1 breast cancer cell line was maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 1%
antibiotics and 10% fetal bovine serum at 37 °C with 5% CO2
flow. The cellular viability and apoptotic behavior of 1% (w/v)
PA gels (with or without 40 µM Dox prepared according to the
procedures described above) were determined by flow
cytometry.
Before seeding the cells, all groups were treated with cell
medium for 1 h, and 4T1 breast cancer cells (5 × 104 cells per
well) were seeded onto 48-well culture plates. The cells were
treated for 24 h and 48 h, and trypsin/collagenase (1 : 1 (v/v))
was then used to degrade the gels and to remove the cells from
the peptide extract. Then, the degraded samples were strained
with falcon strainers (40 μm pore size) and centrifuged at
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4000 rpm for 6 min. The supernatants were removed and the
remaining cells were washed with PBS to remove the cell
medium. The cells were then centrifuged at 4000 rpm for
6 min, the supernatant was discarded, and the cell pellet was
re-suspended using 100 μL of 1× annexin binding buffer. For
the flow cytometry analysis, cells were labeled with Annexin V
and propidium iodide and incubated at room temperature for
15 min. 400 μL of 1× annexin binding buffer was added to all
samples immediately prior to flow cytometry analysis.
4T1 tumor model development and in vivo studies
Animals were maintained in accordance with the guidelines of
the Institutional Animal Care and Use Committee of the
Diskapi Yildirim Beyazit Training and Research Hospital,
Ankara, Turkey and approved by the Institutional Ethical
Committee (IEC) of the Institutional Animal Care and Use
Committee of the Diskapi Yildirim Beyazit Training and
Research Hospital, Ankara, Turkey. A total of 40 female Balb/c
mice (8–10 weeks old) from Adacell Laboratories (Ankara,
Turkey) were used for the drug delivery experiments and histo-
logical studies. Animals were housed in a specific pathogen-
free environment with 12 h light–dark cycles and ad libitum
access to food and water. 4T1 cells were administered to mice
in order to develop an orthotropic mammary carcinoma
model. Just prior to the inoculation, 2 × 106 viable cells were
suspended in 1 mL serum-free RPMI 1640 medium. Cells in
50 µL medium were subcutaneously injected into the second
mammary fat pad on the right side of BALB/c mice using 1/2
inch 26 gauge needles. Tumor formation was observed 8 days
after implantation. The tumor volume was calculated accord-
ing to the following formula: V = 1/2(D × d2) where the tumor
volume was defined as V, D is the measurement of the greatest
longitudinal diameter of the tumor and d is the greatest trans-
verse diameter of the tumor as measured with a digital caliper.
When the tumor volume reached 100 mm3, forty mice were
randomly divided into four groups and treated with Dox
encapsulated 1% (w/v) PA gels or controls (n = 8): Dox/PA, only
Dox, only PA and PBS. Samples were administered via sub-
cutaneous injection adjacent to the tumor tissue at a dose
equivalent of 10 mg Dox per kg body weight. The body weight
(Fig. S7†) and tumor volume were monitored every 3 days.
Animals were sacrificed at day 18.
Histology and immunohistochemical staining
Tissues were fixed in 10% (v/v) formalin and embedded in
paraffin. 5 µm sections were cut using a Leica microtome and
stained with hematoxylin and eosin (H&E). Caspase-3 mediated
apoptosis in tumor tissues of different treatment groups was
evaluated. Slides were dried overnight at 60 °C before depar-
affinization, and then rehydrated through a graded alcohol
series. Sodium citrate buffer (pH 6.0) was used for heat-
induced antigen retrieval. Sections were blocked in 1% Tris
buffered saline (TBS) and 1% bovine serum albumin (BSA)
solution for 2 h at room temperature (RT). Samples were then
treated with the cleaved caspase-3 monoclonal antibody
(1/300) (Asp175) (#9661 Cell Signaling Technology, USA) in TBS
and BSA solution, and subsequently incubated at 4 °C over-
night. Slides were rinsed with TBS and 0.025% Triton-X 100
solution following HRP conjugated goat-anti rabbit secondary
antibody (1 : 500) incubation for 1 h at RT and then washed
with TBS several times. Between each immunostaining step,
slides were washed briefly in TBS buffer (pH 7.6). Controls
were prepared by replacing the primary antibody with TBS
buffer. The staining was developed by using diaminobenzidine
(DAB) as the substrate. The sections were counterstained with
hematoxylin. Bright-field microscopy was used to obtain the
images.
Statistical analysis
All statistical analyses were carried out by one-way or two-way
ANOVA, or an unpaired student’s t-test, whichever applicable.
A p-value of less than 0.05 was determined as statistically
significant.
Results and discussion
Design, synthesis and characterization of PA assemblies and
supramolecular nanofiber gels
Two different PA molecules (E3PA and K3PA, Fig. 1a) were
designed as building blocks of the drug delivery system and
synthesized by the Fmoc solid phase peptide synthesis
method11 (Fig. S1†). The PA molecules consist of an aliphatic
tail, a β-sheet forming motif (–VVAG–) and oppositely charged
amino acids to trigger coassembly through hydrophobic inter-
actions, hydrogen bonding and electrostatic interactions at pH
7.4 in water. Particularly, the overall charge neutralization
within the system, which was determined via zeta potential
measurements of the PA mixtures (E3/K3PA) (Fig. 1b), enables
the formation of the self-supporting supramolecular PA gel
upon mixing the E3PA and K3PA solutions at a 3 : 4 molar ratio
(Fig. 1c) above 0.5% (w/v) PA concentration. The nanofibrous
structural organization within the PA gels prepared at different
concentrations was analyzed via SEM imaging (Fig. 1d and
S2†) and the individual coassembled PA nanofibers were
observed by TEM (Fig. 1e).
The structural organization of the PA coassemblies was
revealed by CD and FTIR measurements. The CD spectra of
the E3/K3PA assemblies exhibited positive and negative peaks
at around 190 and 220 nm respectively, which corresponded to
the formation of twisted β-sheets within PA nanofibers
(Fig. 2a). On the other hand, E3PA and K3PA solutions (which
were used as control groups) did not show any aggregation and
preserved their random coil organization at pH 7.4 in water
(Fig. 2a). FTIR analysis of the PA assemblies also pointed the
β-sheet organization of the coassembled nanofibers with the
observed peaks at around 1632 cm−1 and 1672 cm−1 within
the Amide I region42 complementary to the CD spectra (Fig. 2b
and c).
The concentration dependent viscoelastic behavior of E3/
K3PA assemblies was characterized using dynamic oscillatory
rheology. Time sweep analysis of all groups revealed their gel-
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like behavior, as the storage modulus (G′) values of the
samples were higher than their loss moduli (G′) (Fig. 3a). In
addition, equilibrium storage and loss modulus values of the
PA gels could be adjusted depending on the PA concentration
within the coassembled gels (Fig. 3b). Although these architec-
tures are formed through noncovalent interactions between PA
building blocks, the viscoelasticity of the gel systems could
reach up to 10 kPa and provided them with the mechanical
stability required for their use as drug delivery systems in local
soft tissue applications. In addition, the 1% (w/v) PA nanofiber
gel preserved its mechanical stability upon its injection
through a syringe (Fig. S3†).
Biodegradability of supramolecular PA nanofiber gels
Proteolytic degradation profiles of 1% (w/v) coassembled PA
gels were monitored based on the gel mass change over time
(Fig. S4†). Two different serine proteases, proteinase K and
α-chymotrypsin, were selected owing to their broad specificity
for the cleavage of the peptide bonds, primarily from aromatic
or hydrophobic residues.43 The gels were incubated with
enzyme solutions prepared in Tris buffer at pH 7.4 or only the
buffer as the control group. The solutions were removed and
the remaining gel mass was weighed at determined time inter-
vals (Fig. S4†). The PA gel was rapidly degraded by proteinase
K and only 10% of the gel mass remained at day 25. On the
other hand, the degradation of the PA gel by α-chymotrypsin
was slower compared to proteinase K, and approximately 50%
of the gel had remained at day 25 under the same concen-
trations. In the literature, α-chymotrypsin is generally utilized
to cleave peptide bonds from aromatic residues.44 On the
other hand, proteinase K exhibits activity against aliphatic
amino acids in addition to hydrophobic and aromatic resi-
dues.45 This difference in the degradation behavior of the two
enzymes could be related to the ability of proteinase K to
easily cleave the aliphatic beta sheet forming motif (–VVAG–)
that is present in the interspace between the hydrophobic ali-
phatic tail and hydrophilic amino acid regions of the PA mole-
cules. Additionally, the control group (which is incubated only
with the buffer solution) retains its weight for 25 days,
suggesting that the coassembled system is stable for a con-
siderable period of time in the absence of enzymatic
degradation.
Drug encapsulation and controlled drug release
To encapsulate the Dox molecules within the supramolecular
PA nanofiber gels, the drug solution was initially mixed with
positively charged K3PA and coassembly was subsequently trig-
gered by addition of negatively charged E3PA at pH 7.4
(Fig. 4a). This approach enabled the 100% encapsulation and
homogeneous dispersion of the drug molecules within PA
gels. In addition, the nanofibrous architecture of the gels pro-
vided a suitable nanoporous environment for the controlled
release of small molecules and to sustain the therapeutic level
for local application of the delivery system in soft tissues
(Fig. 4a).
Drug release profiles depending on the PA concentration
within the coassembled PA gels were monitored and quanti-
fied based on the concentration dependent fluorescence inten-
Fig. 1 (a) Chemical representations of E3PA and K3PA molecules, (b) the zeta potential change of the E3PA upon addition of K3PA at pH 7.4 in water,
(c) the supramolecular PA network showing self-supporting gel properties, and (d) SEM and (e) TEM images of the coassembled PA nanonetwork
and nanofibers, respectively.
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sity calibration of the molecules. The sustained release of the
drug molecules through the PA gels was observed for 48 h, and
then in vitro release kinetics slowed down reaching an equili-
brium after 156 h (Fig. 4b). Non-linear transport kinetics of all
PA groups were consistent with non-Fickian release behavior,
which may have resulted from the interactions of Dox with
three different interfaces that are present in the PA system: (i)
the hydrophobic alkyl domain, (ii) hydrophilic amino acids
carrying both negative and positive charges, and (iii) water
molecules entrapped within the system. Non-covalent inter-
actions between Dox molecules and these interfaces may
account for the non-linearity of the transport properties and
prevent the complete release of the encapsulated drug mole-
cules through the gel system. In addition, release kinetics and
the amount of the released molecules under equilibrium con-
ditions were modulated by the PA concentration (Fig. 4c)
which has an effect on both the porosity of the network and
the entanglement of nanofibers46 within the coassembled PA
gel system. Furthermore, PA nanofiber gels preserved their
structural integrity throughout the release experiment under
given conditions for 156 h.
In addition to in vitro bulk release studies, the mobility of
the drug molecules within coassembled PA gels was investi-
gated by FRAP,46 in which fluorescent molecules are photo-
bleached by using a high power laser source and the recovery
of fluorescence intensity at the bleached area is monitored to
estimate the transport parameters of the molecules. Dox
encapsulated gels were prepared at different PA concentrations
in an enclosed system to prevent drying throughout the experi-
mental period. Fluorescence intensity changes were monitored
after the photobleaching of drug molecules (Fig. 5a); and data
analysis was performed using the program developed by
Jönsson et al.47 Diffusion constants of Dox molecules within 3,
2, 1 and 0.5% (w/v) PA nanofiber gels were estimated by
Hankel through transforming the resulting data (Fig. 5b and
S5†). FRAP experiments suggest that the drug release and
mobility of the molecules can be modulated and controlled
depending on the PA concentration. In addition, immobile
fractions of the Dox molecules within the gels were deter-
mined to be 0.56 ± 0.17, 0.26 ± 0.05, 0.19 ± 0.05 and 0.17 ±
0.02, respectively using the FRAP data. The increase in the
immobile Dox molecule amount depending on the PA concen-
tration within the gel systems also shows us the affinity of the
PA network towards the drug molecules, which is consistent
with the non-Fickian transport behavior that the gels exhibit.
Although non-covalent interactions between PA nanofiber gels
and drug molecules resulted in the entrapment of some
Fig. 2 (a) CD spectra of E3PA, K3PA and E3/K3PA, and the FTIR analysis
of the E3/K3PA assembly at pH 7.4 in water (b, c).
Fig. 3 (a) Time sweep analysis of the supramolecular PA nanofiber gels prepared at different concentrations, and (b) equilibrium storage (G’) and
loss moduli (G’’) of the PA gels.
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portion of the molecules within the system, the biodegradab-
ility of the nanofibrous PA system could improve the availability
of the immobile drug molecules via proteolytic degradation of
the PA gel delivery system. On the other hand, 1% (w/v) PA con-
centration was determined for both in vivo and in vitro experi-
ments considering the mechanical stability (Fig. 3), controlled
release and transport properties of the PA nanofiber gels
(Fig. 4 and 5).
In vitro studies
To determine the biocompatibility of the delivery system and
the effects of controlled drug release on cellular viability,
breast cancer cells were cultured on the only PA gel, Dox
encapsulated PA gel (Dox/PA) or uncoated tissue culture plate
(TCP, control). The same amount of Dox encapsulated within
the gels was also directly administered to the cell culture
media as a positive control (only Dox) for 24 h and 48 h. The
only PA gel did not exhibit any cytotoxicity compared to the
TCP control (Fig. 6 and S6†). However, cellular viability had
decreased at 24 h and 48 h for both only Dox and Dox/PA
groups. Although no significant differences were present
between these groups at 24 h, the Dox/PA group was more
effective in inhibiting cellular growth at 48 h, potentially due
to the sustained release of Dox molecules from the gel system.
In addition, the PA nanofiber gel provides suitable protection
for drug molecules and enhances their bioavailability and
activity under in vitro conditions.
In vivo applicability of supramolecular PA nanofiber gels for
the treatment of solid tumors
After examining the biocompatibility of PA gels and controlled
drug release dependent cellular viability under in vitro con-
ditions, the applicability of the Dox/PA gels as a local drug
delivery system was tested in vivo using a solid tumor model.
For this purpose, highly aggressive and metastatic 4T1 breast
cancer cells were subcutaneously injected to the mammary fat
pad of Balb/c mice for tumor growth. When the tumor volume
reached 100 mm3, identical amounts of the 1% (w/v) Dox/PA
gel, only PA gel, Dox solution or PBS (as the control) were
injected to the tumor site, and tumor sizes were measured
every three days using an electronic caliper. The tumor growth
rate was followed for 18 days (Fig. 7a), at which time the
animals were sacrificed for histological analysis of tumors and
other organs (Fig. S8†). The local delivery of Dox molecules by
coassembled PA gels significantly limited tumor growth com-
pared to the direct injection of the drug solution (Fig. 7b). On
Fig. 4 (a) Schematic representation of the drug encapsulation and coassembly of the oppositely charged PA molecules into supramolecular
nanofiber gels, (b) controlled release profile of Dox through the PA gels prepared at different concentrations at pH 7.4 in water, and (c) the release
ratios of the chemotherapeutic drug were modulated depending on the PA concentration within the gels.
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the other hand, PA gels without the drug encapsulation did
not cause additional cytotoxicity compared to PBS control
which indicated the in vivo biocompatibility of the co-
assembled PA nanofiber gels as a local delivery system.
Dox demonstrates its chemotherapeutic activity by inducing
caspase-3 activation, which mediates apoptosis and DNA frag-
mentation through the p53 pathway.48 To reveal the effects of
the administration of the Dox molecules via a controlled deliv-
ery system on the tumor tissue, immunostaining against
caspase-3, which is an apoptotic cell marker, was performed
on tissue sections. Cleaved caspase-3 positive cells were clearly
observed in tumor tissues treated with Dox/PA. Analysis of
tissue sections stained with caspase-3 indicated that the sus-
tained release of the drug molecules through PA gels increased
the number of apoptotic cells within the tumor tissue and
facilitated the activity of the chemotherapeutic Dox molecules
at the local site to a greater extent, compared to the local injec-
tion of the Dox molecules without a controlled delivery system
(Fig. 8). Hematoxylin–eosin staining was also performed to
observe the tissue morphology of the tumor, liver, kidney and
spleen treated with the Dox/PA, and revealed the promoted
activity and reduced side effects of the drug molecules com-
pared to the healthy tissue controls (Fig. S8†).
Conclusions
Advances in developing biocompatible and injectable drug
delivery systems can facilitate the local chemotherapeutic
applications for the treatment of soft-tissue cancer types.
Supramolecular PA nanofiber gels are potential candidates for
Fig. 5 Mathematical fitting results of FRAP experiments: (a) the esti-
mated diffusion constants, and (b) immobile fractions of the drug mole-
cules encapsulated within the PA gels prepared at different
concentrations.
Fig. 6 Cellular viability of (a) the control (TCP), (b) 1% (w/v) PA gel, (c)
1% (w/v) Dox/PA gel and (d) only Dox for 24 h and 48 h.
Fig. 7 (a) Tumor growth of the only Dox, only PA, Dox/PA and non-
treated control groups for 18 days, and (b) the final tumor volume (mm3)
at day 18.
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prolonged local delivery of chemotherapeutics under physio-
logical conditions. In this study, we showed that the PA gels
consisting of coassembled nanofibers with a β-sheet secondary
structure organization could form with facile assembly pro-
perties at pH 7.4 in water through noncovalent interactions
between oppositely charged PA molecules. In addition, con-
trolled drug release characteristics of the PA nanofiber gels
could be modulated depending on the PA concentration and
noncovalent interactions between the PA network and drug
molecules could be used to facilitate the affinity-controlled
release of encapsulated drugs. Biocompatibility and biodegrad-
ability of the PA nanofiber gels were also other advantages of
these architectures for drug delivery. The significant decrease
in the tumor growth rate following the injection of Dox/PA gels
in vivo compared to the other groups also showed the potential
of supramolecular PA nanofiber gels for local chemotherapeu-
tic applications in clinical settings.
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